hAPP Mouse
製品名
hAPP Mouse
製品ID
C002123
系統名
C57BL/6Cya-Appem3(hAPP)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「hAPP Mouse（カタログ番号C002123）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
AAA, AD1, PN2, ABPP, APPI, CVAP, ABETA, PN-II, preA4, CTFgamma, alpha-sAPP
NCBI ID
染色体
Chr 21
MGI ID
さらに
系統詳細
The APP gene encodes the Amyloid Precursor Protein, a type I transmembrane glycoprotein that is ubiquitously expressed but reaches its highest levels in the central nervous system, particularly in the cerebral cortex and hippocampus. Following translation, the APP protein is proteolytically processed via two primary pathways: the non-amyloidogenic pathway, which prevents Aβ formation, and the amyloidogenic pathway, where sequential cleavage by β-secretase (BACE1) and γ-secretase releases amyloid-beta (Aβ) peptides [1]. While its precise physiological role remains an area of active research, APP is known to function in synaptic formation and repair, anterograde neuronal transport, and cell-to-cell adhesion [2]. Pathological mutations or duplications of the APP gene are primary drivers of Alzheimer’s Disease (AD) and Cerebral Amyloid Angiopathy (CAA), characterized by the extracellular accumulation of Aβ plaques and vascular deposits that lead to neurodegeneration and cognitive decline [3].
The hAPP mouse is a humanized model generated using gene-editing technology. The region downstream of the mouse App signal peptide-coding sequence to a portion of intron 1 was replaced with the “Human APP CDS-3'UTR of Human APP-WPRE-BGH pA” cassette, while the mouse App signal peptide-coding sequence was retained. This model is suitable for studying neurodegenerative diseases such as Alzheimer's disease (AD), as well as for the research, development, and efficacy evaluation of AD therapeutic strategies targeting APP. Cyagen also offers huAPP-Aβ mice (Catalog No.: C002031), providing an alternative model for APP/Aβ-related research. The two models feature distinct humanization designs: the hAPP mouse incorporates a human APP CDS expression cassette, whereas the huAPP-Aβ mouse carries a genomic replacement in which the corresponding mouse App genomic region was replaced with its human APP genomic counterpart. The appropriate model can be selected based on the humanized region and construct design, according to the specific drug target and research objectives.
参考文献
Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007 Nov 15;2:22.
Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006 Jul 3;1:5.
Grangeon L, Charbonnier C, Zarea A, Rousseau S, Rovelet-Lecrux A, Bendetowicz D, Lemaitre M, Malrain C, Quillard-Muraine M, Cassinari K, Maltete D, Pariente J, Moreaud O, Magnin E, Cretin B, Mackowiak MA, Sillaire AR, Vercelletto M, Dionet E, Felician O, Rod-Olivieri P, Thomas-Antérion C, Godeneche G, Sauvée M, Cartz-Piver L, Le Ber I, Chauvire V, Jonveaux T, Balageas AC, Laquerriere A, Duyckaerts C, Vital A, de Paula AM, Meyronet D, Guyant-Marechal L, Hannequin D, Tournier-Lasserve E, Campion D; CNR-MAJ collaborators; Nicolas G, Wallon D. Phenotype and imaging features associated with APP duplications. Alzheimers Res Ther. 2023 May 11;15(1):93.
系統作製戦略
The region downstream of the mouse App signal peptide-coding sequence to a portion of intron 1 was replaced with the “Human APP CDS-3'UTR of Human APP-WPRE-BGH pA” cassette, while the mouse App signal peptide-coding sequence was retained.
Figure 1. Gene editing strategy for hAPP mice.
適用分野
Research on Alzheimer's disease (AD);
Research on Cerebral Amyloid Angiopathy (CAA);
Preclinical research such as the development, screening, and efficacy evaluation of APP-targeted therapeutic drugs.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。